A citation-based method for searching scientific literature

Alexandru Oprita, Stefania-Carina Baloi, Georgiana-Adeline Staicu, Oana Alexandru, Daniela Elise Tache, Suzana Danoiu, Elena Simona Micu, Ani-Simona Sevastre. Int J Mol Sci 2021
Times Cited: 10







List of co-cited articles
48 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
40

The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
40


Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
Wolfgang Wick, Vinay K Puduvalli, Marc C Chamberlain, Martin J van den Bent, Antoine F Carpentier, Lawrence M Cher, Warren Mason, Michael Weller, Shengyan Hong, Luna Musib,[...]. J Clin Oncol 2010
327
30

A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.
Yazmin Odia, Fabio M Iwamoto, Argirios Moustakas, Tyler J Fraum, Carlos A Salgado, Aiguo Li, Teri N Kreisl, Joohee Sul, John A Butman, Howard A Fine. J Neurooncol 2016
24
30

Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines.
Oana Alexandru, Ani-Simona Sevastre, Juan Castro, Stefan-Alexandru Artene, Daniela Elise Tache, Oana Stefana Purcaru, Veronica Sfredel, Ligia Gabriela Tataranu, Anica Dricu. Int J Mol Sci 2019
10
30

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Ingo K Mellinghoff, Maria Y Wang, Igor Vivanco, Daphne A Haas-Kogan, Shaojun Zhu, Ederlyn Q Dia, Kan V Lu, Koji Yoshimoto, Julie H Y Huang, Dennis J Chute,[...]. N Engl J Med 2005
20

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
20

Temozolomide: mechanisms of action, repair and resistance.
Jihong Zhang, Malcolm F G Stevens, Tracey D Bradshaw. Curr Mol Pharmacol 2012
367
20

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Jianjiong Gao, Bülent Arman Aksoy, Ugur Dogrusoz, Gideon Dresdner, Benjamin Gross, S Onur Sumer, Yichao Sun, Anders Jacobsen, Rileen Sinha, Erik Larsson,[...]. Sci Signal 2013
20

Targeting cellular pathways in glioblastoma multiforme.
Joshua R D Pearson, Tarik Regad. Signal Transduct Target Ther 2017
114
20


Advances in Research of Adult Gliomas.
Alina Finch, Georgios Solomou, Victoria Wykes, Ute Pohl, Chiara Bardella, Colin Watts. Int J Mol Sci 2021
5
40


The effect of temozolomide in combination with doxorubicin in glioblastoma cells in vitro.
Cristina Horescu, Catalina Elena Cioc, Cristian Tuta, Ani-Simona Sevastre, Daniela Elise Tache, Oana Alexandru, Stefan-Alexandru Artene, Suzana Danoiu, Anica Dricu, Purcaru Stefana Oana. J Immunoassay Immunochem 2020
4
50

Helianthin induces antiproliferative effect on human glioblastoma cells in vitro.
Oana Alexandru, Laura Dragutescu, Ligia Tataranu, Vasile Ciubotaru, Ani Sevastre, Ada Maria Georgescu, Oana Purcaru, Suzana Danoiu, L Magnus Bäcklund, Anica Dricu. J Neurooncol 2011
5
40

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Selcuk Onur Sumer, Bülent Arman Aksoy, Anders Jacobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson,[...]. Cancer Discov 2012
20

Growth factor receptors signaling in glioblastoma cells: therapeutic implications.
Mia Carapancea, Oana Alexandru, Ani S Fetea, Laura Dragutescu, Juan Castro, Ada Georgescu, A Popa-Wagner, Magnus L Bäcklund, Rolf Lewensohn, Anica Dricu. J Neurooncol 2009
20
20

Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches.
Oana Alexandru, Cristina Horescu, Ani-Simona Sevastre, Catalina Elena Cioc, Carina Baloi, Alexandru Oprita, Anica Dricu. Contemp Oncol (Pozn) 2020
11
20

Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
Milan G Chheda, Patrick Y Wen, Fred H Hochberg, Andrew S Chi, Jan Drappatz, April F Eichler, Daniel Yang, Rameen Beroukhim, Andrew D Norden, Elizabeth R Gerstner,[...]. J Neurooncol 2015
25
20

A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.
Yazmin Odia, Joohee Sul, Joanna H Shih, Teri N Kreisl, John A Butman, Fabio M Iwamoto, Howard A Fine. CNS Oncol 2016
13
20

Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment.
Alisa Madalina Popescu, Oana Alexandru, Corina Brindusa, Stefana Oana Purcaru, Daniela Elise Tache, Ligia Gabriela Tataranu, Citto Taisescu, Anica Dricu. Int J Clin Exp Pathol 2015
24
20

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
Edward B Reilly, Andrew C Phillips, Fritz G Buchanan, Gillian Kingsbury, Yumin Zhang, Jonathan A Meulbroek, Todd B Cole, Peter J DeVries, Hugh D Falls, Christine Beam,[...]. Mol Cancer Ther 2015
51
20

Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Hui K Gan, David A Reardon, Andrew B Lassman, Ryan Merrell, Martin van den Bent, Nicholas Butowski, Zarnie Lwin, Helen Wheeler, Lisa Fichtel, Andrew M Scott,[...]. Neuro Oncol 2018
35
20

AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.
Kevin J Hamblett, Carl J Kozlosky, Sophia Siu, Wesley S Chang, Hua Liu, Ian N Foltz, Esther S Trueblood, David Meininger, Taruna Arora, Brian Twomey,[...]. Mol Cancer Ther 2015
52
20

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Andrew B Lassman, Martin J van den Bent, Hui K Gan, David A Reardon, Priya Kumthekar, Nicholas Butowski, Zarnie Lwin, Tom Mikkelsen, Louis B Nabors, Kyriakos P Papadopoulos,[...]. Neuro Oncol 2019
49
20

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
David A Reardon, Annick Desjardins, James J Vredenburgh, Sridharan Gururangan, Allan H Friedman, James E Herndon, Jennifer Marcello, Julie A Norfleet, Roger E McLendon, John H Sampson,[...]. J Neurooncol 2010
152
20

Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Raghupathy Vengoji, Muzafar A Macha, Rama Krishna Nimmakayala, Satyanarayana Rachagani, Jawed A Siddiqui, Kavita Mallya, Santhi Gorantla, Maneesh Jain, Moorthy P Ponnusamy, Surinder K Batra,[...]. J Exp Clin Cancer Res 2019
30
20

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
David A Reardon, Louis B Nabors, Warren P Mason, James R Perry, William Shapiro, Petr Kavan, David Mathieu, Surasak Phuphanich, Agnieszka Cseh, Yali Fu,[...]. Neuro Oncol 2015
92
20

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
James Schuster, Rose K Lai, Lawrence D Recht, David A Reardon, Nina A Paleologos, Morris D Groves, Maciej M Mrugala, Randy Jensen, Joachim M Baehring, Andrew Sloan,[...]. Neuro Oncol 2015
221
20

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
Zhenyi An, Ozlem Aksoy, Tina Zheng, Qi-Wen Fan, William A Weiss. Oncogene 2018
168
20

Lomustine and Bevacizumab in Progressive Glioblastoma.
Wolfgang Wick, Thierry Gorlia, Martin Bendszus, Martin Taphoorn, Felix Sahm, Inga Harting, Alba A Brandes, Walter Taal, Julien Domont, Ahmed Idbaih,[...]. N Engl J Med 2017
316
20

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Henry S Friedman, Michael D Prados, Patrick Y Wen, Tom Mikkelsen, David Schiff, Lauren E Abrey, W K Alfred Yung, Nina Paleologos, Martin K Nicholas, Randy Jensen,[...]. J Clin Oncol 2009
20

Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Yuji Piao, Soon Young Park, Verlene Henry, Bryan D Smith, Ningyi Tiao, Daniel L Flynn, John F de Groot. Neuro Oncol 2016
41
20

The Influence of EGFR Inactivation on the Radiation Response in High Grade Glioma.
Oana Alexandru, Stefana Oana Purcaru, Ligia Gabriela Tataranu, Laura Lucan, Juan Castro, Catalin Folcuţi, Stefan-Alexandru Artene, Cristian Tuţă, Anica Dricu. Int J Mol Sci 2018
9
22

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Eudocia Q Lee, David A Reardon, David Schiff, Jan Drappatz, Alona Muzikansky, Sean A Grimm, Andrew D Norden, Lakshmi Nayak, Rameen Beroukhim, Mikael L Rinne,[...]. Neuro Oncol 2015
66
20

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Giuseppe Lombardi, Gian Luca De Salvo, Alba Ariela Brandes, Marica Eoli, Roberta Rudà, Marina Faedi, Ivan Lolli, Andrea Pace, Bruno Daniele, Francesco Pasqualetti,[...]. Lancet Oncol 2019
88
20

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Tracy T Batchelor, Elizabeth R Gerstner, Xiaobu Ye, Serena Desideri, Daniel G Duda, David Peereboom, Glenn J Lesser, Sajeel Chowdhary, Patrick Y Wen, Stuart Grossman,[...]. Neuro Oncol 2017
15
20

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Sith Sathornsumetee, Annick Desjardins, James J Vredenburgh, Roger E McLendon, Jennifer Marcello, James E Herndon, Alyssa Mathe, Marta Hamilton, Jeremy N Rich, Julie A Norfleet,[...]. Neuro Oncol 2010
156
20

A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Evanthia Galanis, S Keith Anderson, Erin L Twohy, Xiomara W Carrero, Jesse G Dixon, David Dinh Tran, Suriya A Jeyapalan, Daniel M Anderson, Timothy J Kaufmann, Ryan W Feathers,[...]. Cancer 2019
24
20

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII.
Mark Rosenthal, Richard Curry, David A Reardon, Erik Rasmussen, Vijay V Upreti, Michael A Damore, Haby A Henary, John S Hill, Timothy Cloughesy. Cancer Chemother Pharmacol 2019
11
20

Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.
Maria Teresa Solomón, Julio César Selva, Javier Figueredo, José Vaquer, Carolina Toledo, Nelson Quintanal, Silvia Salva, Rafael Domíngez, José Alert, Jorge Juan Marinello,[...]. BMC Cancer 2013
45
20

NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
David M Peereboom, Manmeet S Ahluwalia, Xiaobu Ye, Jeffrey G Supko, Sarah L Hilderbrand, Surasak Phuphanich, L Burt Nabors, Myrna R Rosenfeld, Tom Mikkelsen, Stuart A Grossman. Neuro Oncol 2013
55
20

Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).
Andrew B Lassman, Stephanie L Pugh, Mark R Gilbert, Kenneth D Aldape, Sandrine Geinoz, Jan H Beumer, Susan M Christner, Ritsuko Komaki, Lisa M DeAngelis, Rakesh Gaur,[...]. Neuro Oncol 2015
70
20

A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma.
Manfred Westphal, Oliver Heese, Joachim P Steinbach, Oliver Schnell, Gabriele Schackert, Maximilian Mehdorn, Dirk Schulz, Matthias Simon, Uwe Schlegel, Christian Senft,[...]. Eur J Cancer 2015
100
20

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Tracy T Batchelor, Paul Mulholland, Bart Neyns, L Burt Nabors, Mario Campone, Antje Wick, Warren Mason, Tom Mikkelsen, Surasak Phuphanich, Lynn S Ashby,[...]. J Clin Oncol 2013
325
20

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
Martin van den Bent, Hui K Gan, Andrew B Lassman, Priya Kumthekar, Ryan Merrell, Nicholas Butowski, Zarnie Lwin, Tom Mikkelsen, Louis B Nabors, Kyriakos P Papadopoulos,[...]. Cancer Chemother Pharmacol 2017
63
20

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto,[...]. Lancet Oncol 2017
419
20

Importance of PKCδ signaling in fractionated-radiation-induced expansion of glioma-initiating cells and resistance to cancer treatment.
Min-Jung Kim, Rae-Kwon Kim, Chang-Hwan Yoon, Sungkwan An, Sang-Gu Hwang, Yongjoon Suh, Myung-Jin Park, Hee Young Chung, In Gyu Kim, Su-Jae Lee. J Cell Sci 2011
33
10



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.